NEMLUVIO relieves itch fast—as soon as 48 hours* in some patients—with skin healing that lasts1,2

Fast Itch Relief1

See how NEMLUVIO® significantly improved itch in both pivotal and long-term studies1,2

VIEW THE DATA  

Lasting Skin Healing2

Discover how NEMLUVIO healed most PN nodules for patients with PN2

SEE THE DIFFERENCE  

Sleep Improvement3

Patients saw meaningful improvements in their sleep while taking NEMLUVIO3

VIEW THE DATA  

Favorable Safety Profile4

NEMLUVIO offers a favorable safety profile and requires no preliminary lab evaluations or ongoing lab monitoring4

REVIEW SAFETY PROFILE  

PP-NRS response was achieved at 48 hours in 17.2% with NEMLUVIO vs 3.7% with placebo. Data from pooled post-hoc analysis of daily PP-NRS improvement reported in Phase 3 clinical studies (OLYMPIA 1 and 2). PP-NRS response defined as a ≥4-point improvement from baseline. No conclusions regarding efficacy should be made based on these results.1

A Trial Program Designed to Capture the Complexity of PN3,4

Explore the design of OLYMPIA, the largest controlled clinical trial program in PN5

REVIEW TRIAL 

Experiencing a new reality

See how Chris relieved his unrelenting itch and achieved lasting skin healing with NEMLUVIO

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.